Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Down 8.7% - Should You Sell?

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) fell 8.7% during mid-day trading on Friday . The stock traded as low as $5.97 and last traded at $5.98. 832,978 shares traded hands during mid-day trading, a decline of 35% from the average session volume of 1,277,882 shares. The stock had previously closed at $6.55.

Wall Street Analysts Forecast Growth

Several research firms have commented on TERN. BMO Capital Markets reaffirmed an "outperform" rating and issued a $26.00 price target (up previously from $19.00) on shares of Terns Pharmaceuticals in a report on Monday, September 16th. HC Wainwright boosted their target price on Terns Pharmaceuticals from $5.50 to $7.50 and gave the stock a "neutral" rating in a report on Wednesday. JMP Securities upped their target price on shares of Terns Pharmaceuticals from $15.00 to $20.00 and gave the stock a "market outperform" rating in a research report on Tuesday, September 10th. Finally, Oppenheimer initiated coverage on Terns Pharmaceuticals in a research note on Thursday, October 31st. They set an "outperform" rating and a $82.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $27.25.

Terns Pharmaceuticals Stock Down 9.8 %

The firm has a 50 day moving average price of $8.06 and a two-hundred day moving average price of $7.46. The company has a market cap of $501.99 million, a price-to-earnings ratio of -5.02 and a beta of -0.32.

Insiders Place Their Bets

In related news, Director Jill M. Quigley sold 17,235 shares of the business's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $10.00, for a total value of $172,350.00. Following the transaction, the director now directly owns 15,000 shares of the company's stock, valued at approximately $150,000. The trade was a 53.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Mark J. Vignola sold 10,000 shares of the firm's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $11.00, for a total transaction of $110,000.00. Following the sale, the chief financial officer now owns 91,940 shares of the company's stock, valued at $1,011,340. This trade represents a 9.81 % decrease in their position. The disclosure for this sale can be found here. Insiders own 15.10% of the company's stock.

Institutional Trading of Terns Pharmaceuticals

Large investors have recently bought and sold shares of the company. nVerses Capital LLC bought a new position in shares of Terns Pharmaceuticals during the 3rd quarter worth $48,000. Simplicity Wealth LLC bought a new position in Terns Pharmaceuticals in the 2nd quarter worth approximately $72,000. Sio Capital Management LLC bought a new stake in Terns Pharmaceuticals during the 3rd quarter valued at $83,000. Walleye Trading LLC purchased a new stake in shares of Terns Pharmaceuticals during the first quarter worth $98,000. Finally, Kennedy Capital Management LLC bought a new position in shares of Terns Pharmaceuticals in the first quarter worth $101,000. 98.26% of the stock is owned by hedge funds and other institutional investors.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.